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OBJECTIVES: In Uganda, mother to child transmission (MTCT) of HIV is responsible
for approximately 25,000 infections among newborns annually and is the third
leading cause of new infections. This analysis attempts to quantify the financial
and disease burden associated with MTCT of HIV in Uganda. METHODS: Whereas
HIV-negative infants have a life expectancy at birth ranging from 52.2 years for
males and 54.3 years for females, the life expectancy of HIV-positive infants varies
from 2 years in the absence of antiretroviral therapy (ART) to about 14.2 years with
ART. Approximately 18% of eligible children in Uganda have access to ART, at an
annual treatment cost of US$328. Lifetime health-care costs of HIV-positive un-
treated infants are assumed to be US$495. The model calculates years of life lost
(YLL) as the difference in life-expectancy between HIV-positive and HIV-negative
newborns and years of life lived with disability (YLD) by applying the relevant
disability weights of 0.123 for each year lived with HIV and 0.5 for the last year of life
with AIDS. All costs and life years are discounted at 3% annually. RESULTS: The
total annual disease burden resulting from mother to child transmission of HIV is
estimated at 592,480 disability adjusted life years (DALY’s), which is defined as the
sum of YLL: 572,662 and YLD: 19,818. The discounted net present value of future
health care costs associated with mother to child transmission of HIV is estimated
at US$27.3 Million. CONCLUSIONS: Mother to child transmission of HIV is associ-
ated with a substantial mortality and morbidity burden in Uganda. The financial
burden is also worrisome in a country with annual health expenditures of US$24
per capita (circa US$ 830 Million total). Cost-effective strategies to reduce the inci-
dence of MTCT that can be scaled-up nationally are urgently needed.
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OBJECTIVES: To determine the cost of non-CF bronchiectasis patients enrolled in a
managed care plan. METHODS: Data were obtained from a large employer-based
claims database. A cohort of bronchiectasis patients (cases) with and without acute
exacerbations was identified using ICD-9 494.0 and 494.1 codes and matched (1:3)
on demographics to those without the disease (controls) from January 1, 2005-
December 31, 2009. Index event for cases were defined as the first medical claim of
bronchiectasis during the study period and controls were assigned the same index
event to whom they were matched. Cases had no medical claim for cystic fibrosis
and chronic obstructive pulmonary disorder 12 months prior (baseline) and post
index event. Medical resource use and expenditures were estimated for 12 months
before and after index event. All statistical tests were conducted using SAS 9.2.
RESULTS: The final study sample included 9,146 cases and 27,438 matched con-
trols. 64% and 50% of the sample was females and between 45-64 years of age at
index date, respectively. 37%, 29%, and 27% of the sample was enrolled in a POS,
HMO, or PPO type of health plan. Overall comorbidity burden as measured by the
Charlson comorbidity score and respiratory conditions other than bronchiectasis
were significantly (p.001) greater at baseline among cases vs. controls. The incre-
mental overall ($2,128 vs. $783) and respiratory-related ($896 vs. $100) costs were
significantly (p.001) greater among cases vs. controls. The difference was primar-
ily driven by an increase in outpatient care visits (2.21 vs. 0.43), emergency room
visits (0.31 vs. 0.08) and pharmacy scripts (3.58 vs. 0.83) in the post-index period vs.
baseline in cases vs. controls. CONCLUSIONS: The study found that overall incre-
mental economic impact of non-CF bronchiectasis to a health plan was $1345 per
patient. Further research needs to identify the impact of current treatment on the
burden of the disease.
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OBJECTIVES:To analyze the changes in the antiretroviral pharmacotherapy during
2006-2010 and its impact on cost and disease control of HIV/AIDS patients in
Bulgaria.METHODS:Micro costing approach was used based on retrospective anal-
ysis of patients’ records in major clinic for immunosuppressed patients at the
University hospital of infectious and parasitic diseases in Sofia. Information was
gathered for the way of diseases transmission, antiretroviral combinations and
their cost, CD4 count and viral load per patient per year. It was evaluated the
changes in the dosage regimes, cost of therapy and its influence on CD4 count and
viral load. RESULTS: On total 162 patients were included in the study. Nearly 40
different dosage regimes were identified and all of them are combinations of 3 or 4
medicines. During the period were introduces 3 new antiretroviral medicines
(tenofovir, emtricitabin, darunavir). The average yearly cost of pharmacotherapy
(all regimes and patients) is increasing from 155 837.64 euro to 319 571.76 euro
during 2006 - 2010 due to switch of the therapy for some of the patients to newer
medicines because of drug toxicity, resistance or other reasons. All newly regis-
tered patients are treated with the new antiretroviral products and their yearly cost
of therapy is 178251.12 euro. Introduction of the new medicines led to the increase
in total pharmacotherapy cost with 291 89.64 euro, but also to better control mea-
sured with the increase in CD4 count (500) and sustained suppression of vial load
to 20 in 45.46% of patients. CONCLUSIONS: HIV/AIDS remain costly diseases for
the Bulgarian population but new medicines led to better control on its progress
and thus could save further hospital cost.
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OBJECTIVES: Respiratory syncytial virus (RSV) is increasingly recognized as an
important cause of morbidity, mortality and health-care resource use in the el-
derly. Therefore we determined whether there are specific levels of vaccine cost
and effectiveness for which a hypothetical RSV-vaccine for Dutch elderly could be
cost-effective.METHODS: The annual excess RSV-associated age- and risk-specific
burden was estimated using a rate-difference method. Different vaccination strat-
egies were evaluated, for various levels of vaccine effectiveness and different levels
of willingness to pay per quality-adjusted life year gained (QALY). Outcome mea-
sures included costs, QALYs, life years gained (LYGs), and the amount of money
that can be spent per vaccination, while remaining cost-effective. RESULTS: Sig-
nificant excess RSV-associated deaths, hospitalisations, GP-visits and antibiotic
prescriptions were found. The burden of RSV increased with age and was higher for
high-risk (HR) elderly than for low-risk (LR) elderly. For several scenarios vaccina-
tion of the Dutch elderly appeared to be cost-effective. Using base-case assump-
tions, the amount of money that can be spent per vaccination, while remaining
cost-effective, ranged from €26 when vaccinating all 60 elderly to €68 when vac-
cinating only 85 elderly, for a willingness to pay of €50,000 per QALY and a vaccine
effectiveness of 70%. For HR-elderly only these estimates ranged from €52 to €99.
CONCLUSIONS: Vaccination of Dutch elderly with a hypothetical RSV vaccine was
found cost-effective for several scenarios. Vaccination is more likely to be cost-
effective when vaccinating only HR elderly than when vaccinating all elderly, de-
spite a decreased life expectancy and quality of life and a decreased effectiveness
of the vaccine assumed in HR-elderly in the model. This study shows the major
burden of RSV in the Dutch elderly, potential cost-effectiveness of vaccination,
stressing the need to have an effective vaccine available shortly.
PIN35
COSTS OF MANAGING GENITAL WARTS IN THE UK
Carroll S1, Charman F1, Lanitis T2, Brown R3
1Sanofi-Pasteur MSD, Maidenhead, Berkshire, UK, 2United BioSource Corp, London, Middlesex,
UK, 3United BIosource Corp, Bethesda, MD, USA
OBJECTIVES: Cases of genital warts (GW), caused by human papillomavirus (HPV),
remains a significant problem in the UK. Costs to the National Health Service (NHS)
to manage GW have been recently estimated, but studies excluded treatment by
General Practitioners (GP) and costed resources without inclusion of full staff time
and overheads thereby underestimating the full cost impact. This study estimates
the cost of GW management taking account of all identified GW cases seeking care
and applying the full NHS cost algorithm. METHODS: The number of GW cases
obtained from the surveillance of Genitourinary Medicine (GUM) clinics by Health
Protection Agency (HPA) and estimated number of GP visits (using THIN data) for
GW were combined and projected to 2010. The number of visits and therapy re-
quired for GW management were estimated by GUM experts for standard and
hard-to-treat patients. NHS payment by results (PbR) tariffs were applied to esti-
mate GUM resource costs and GP visit and therapy costs estimated from PSSRU and
BNF data. RESULTS: Extrapolating to 2010, there were 173,077 GUM clinic (33.5%
recurrent, 11% persistent) and 16,882 primary care GW episodes excluding referrals
to GUM. Approximately 2% of GUM cases were estimated to be hard-to-treat, re-
quiring additional visits and resources. Resulting NHS costs were £52.4 million
(average £273/female; £278/male patient). The proportion hard-to-treat was the
most sensitive variable for overall national costs.CONCLUSIONS:The £52.4 million
includes the full per patient costs for GUM clinics and costs for GP visits not previ-
ously estimated. This is higher than previous estimates and reflective of real NHS
costs. The full cost of GW management is important to understand and quantify
when considering the potential value of introducing a quadrivalent HPV vaccina-
tion in the UK. This is relevant from both a public health and health economic
perspective.
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OBJECTIVES: Surgical site infections (SSIs) are a significant burden to healthcare
systems negatively affecting Medicare reimbursement, quality and hospital repu-
tation. This study quantifies the economic impact of SSIs across multiple institu-
tions in the United States (US) using more up-to-date real-world data METHODS:
The economic impact of SSIs was evaluated in following surgeries (colon, hernia,
CABG, shunt, abdominal and vaginal hysterectomy, c-section, hip and knee pros-
thesis, spinal fusion, abdominoplasty and breast surgery). The data source was the
Premier Perspective™ Comparative Database, a national administrative discharge
database (2007-2010) from about 500 hospitals throughout the US. The SSIs were
identified by a combination of post-operative infection diagnosis codes, or postop-
erative prescription of selected antimicrobial drugs with treatment duration 5
days. The outcomes included rates of SSI by surgical category, the impact of SSI on
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length of stay (LOS) and costs. Results were projected to the national level. Gener-
alized linear models were used for the analysis. Covariates included the baseline
patient-level surgical risk factors and hospital characteristics. RESULTS: SSI inci-
dence was highest among colon surgery [12.0%, 95%CI:11.78-12.2%0)] and CABG
[6.1%; 95%CI:5.88-6.2%)] cases, and lowest among C-section [0.3%; 95%CI:0.28-
0.31%)] and vaginal hysterectomy [0.16%; 95%CI:0.13-0.2%)] cases. The projected
national rates captured by Premier database were similar to the rates reported by
the National Health Safety Network reported rates. Among all surgical procedures,
health resource use associated with CABG and colon surgery cases were most
affected by SSI. SSI resulted on an average 10.58 [SD 2.78; (95%CI:10.56-10.60)] days
and 9.72 [SD 3.43; (95%CI:9.70-9.74)] days of additional LOS and $38,796 [SD $8,555;
(95%CI:$38,741-$38,850)] and $19,349 [SD $5,720; (95%CI:$19,315-$19,383)] of addi-
tional costs in CABG and colon procedures respectively. CONCLUSIONS: Despite
rise in infection control practices postoperative SSIs continue to remain associated
with significant increases in LOS and hospitalization costs.
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OBJECTIVES: Approximately 3% of the global population is infected with the hep-
atitis C virus. 20% of the patients will develop cirrhosis within 20 years of infection,
and these patients have a 1% to 5% risk per year of developing hepatocellular
carcinoma (HCC). Standard treatment for hepatitis C is pegylated interferon com-
bined with ribavirin. The objective of this study was to obtain an understanding of
the resource utilisation and costs associated with chronic hepatitis C in Sweden.
METHODS: A literature review was conducted to identify resource utilisation and
costs of chronic hepatitis C in Sweden. The MEDLINE, EMBASE, NHS EED and Co-
chrane CCTR databases were searched. To validate the results of the literature
review and fill gaps in the evidence base, interviews were conducted with eight
clinicians and one nurse specialised in the areas of infection, gastroenterology or
transplantation medicine. The Skåne price list was primarily used to obtain the
unit costs. RESULTS: Twelve publications were relevant for inclusion in the review.
There was a lack of resource utilisation data for certain disease stages, primarily
decompensated cirrhosis and HCC, and for updated unit costs, in these publica-
tions. Also, no studies reported indirect costs associated with chronic hepatitis C in
Sweden. The pooled data from the literature review and the interviews indicated a
direct cost per year of EUR 300 for mild disease, EUR 400 for moderate disease, EUR
900 for compensated cirrhosis, EUR 13,000 for decompensated cirrhosis, EUR 20,000
for HCC and EUR 120,000 for liver transplantation (including one-year follow up).
CONCLUSIONS: Chronic hepatitis C is associated with high rates of health care
utilisation. The driver of the direct medical costs is the management of long-term
consequences including cirrhosis, HCC and liver transplantation. More efficient
therapies with higher cure rates could potentially result in long-term cost savings
by reducing severe complications.
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OBJECTIVES: Treatment of chronic hepatitis C infection is well established and will
be expanded to triple treatment with new drugs like hepatitis C virus (HCV) pro-
tease inhibitors in Germany in fall 2011. Costs related to the current HCV guidelines
will be a basis for further health economic analyses needed for pricing strategies
but are not available yet. The aim of this study is to analyse the costs associated
with diagnosis, treatment and monitoring of HCV infected patients according to
the 2010 German S3-consensus guideline considering HCV genotype and length of
therapy. METHODS: Patients with chronic HCV infection were divided in patients
with 1) normal transaminases; 2) elevated transaminases; 3) compensated cirrho-
sis; and 4) decompensated cirrhosis. Direct costs according to the actual 2010 HCV
German guideline were analysed for basic diagnostic procedures, monitoring and
treatment for patient groups 1-3. Costs were modelled according to treatment
duration (16 to 72 weeks) depending on the sustained viral response and HCV
genotype. Costs were calculated according to the German outpatient fee scale
EBM-2010. RESULTS: Costs for basic diagnostics including determination of HCV
genotype and diagnosis of potential hepatic comorbidities accounted for €401 per
patient. Monitoring costs accounted for €596 – €1173 depending on length of ther-
apy. Pharmaceutical costs accounted for the largest part of the costs (€7,709 –
€34,692). The total costs of a 16-week treatment including basic diagnostics, mon-
itoring and pharmaceutical costs accounted for €8,706, €12,734 for a 24-week treat-
ment, €24,529 for a 48-week treatment and €36,266 for 72-week treatment.
CONCLUSIONS: State of the art and guideline cost evaluation for treatment of HCV
infection show high costs for optimal and viral response guided therapy. These
data can be used for further investigation of real life costs and costs of new triple
treatment strategies in HCV treatment.
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OBJECTIVES: The cost analysis of ten schemes antibiotic therapy (AT) in patients
with acute peritonitis was conducted. These schemes are recommended by the
Clinical Protocol of acute peritonitis treatment (MHO of Ukraine, order 1297,
02.04.2010) for use in practice. METHODS: The schemes of antibacterial therapy
are: I – ertapenem (1,0 gr intravenously (iv.) 1 time/day); II – cefotaxim (1,0 gr im. 3
times/day and metronidazol 100 ml (sol. 0,5%) iv. 2 times/day); III – amoxicillin
clavulanate (1,2 gr 3 times/day); IV – moxifloxacin (400 mg 1 time/day); V – levo-
floxacin (500 mg iv. 1 time/day and metronidazol 100 ml (sol.0,5%) iv. 2 times/day);
VI – cefepim (2,0 gr iv. 2 times/day and metronidazol 100 ml (sol.0,5%) iv. 2 times/
day; VII – cefoperazone sulbactam (2,0 gr 3 times/day); VIII – meropenem (500 mg
iv. 4 times/day); IX – imipenem  cilastatin (500 mg/500 mg iv. 4 times/day); X –
ciprofloxacin 400 mg iv. and metronidazol 100 ml (sol.0,5%) iv. 2 times/day. Three
variants for each scheme were calculated: the schemes with original drugs, the
schemes with generics and the schemes with ukrainian generics. Doses and dura-
tion of AT were calculated in accordance with the Clinical Protocol of acute perito-
nitis treatment. RESULTS: The costs range of treating one patient with acute peri-
tonitis with original drugs is 3891 UAN (scheme I) - 7994 UAN (scheme VI). The costs
range with generics of ukrainian production is 1924 UAN (scheme V) - 5413 UAN
(scheme VIII) (1 EUR 11,65 UAN).CONCLUSIONS: The costs of treatment schemes
for patients with acute peritonitis with use of less expensive generic drugs are not
always cheaper than the costs of original drugs using. The optimal schemes for
treatment of patients with acute peritonitis were selected.
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OBJECTIVES: Seventy-nine percent of the skin and soft tissue infections (SSTI) are
caused by staphylococcus aureus, from which 1/3 is methicilin-resistant staphylo-
coccus aureus (MRSA). This study aims to compare SSTI-MRSA treatment costs
with linezolid versus branded and generic vancomycin under the Brazilian public
payer perspective.METHODS:A cost comparison study was performed to compare
linezolid versus generic and branded vancomycin. As supported by clinical studies,
overall treatment duration of 15 days with linezolid and 14 days with vancomycin
was considered, using PO linezolid after a minimum 4-days cycle of IV infusion
while vancomycin (1g bid) was entirely IV. A decision-tree model simulated SSTI-
MRSA treatment assuming linezolid (600mg bid) IV can be switched to PO after
4-days and patients can be discharged if PO is implemented at physician discretion.
Length of stay (LOS) and IV linezolid duration were ranged in one-way sensitivity
analysis. Only direct medical costs were included in the analysis (hospital charges,
medical visits, medical supplies and drug acquisition costs) and unit costs were
obtained from Brazilian official price lists (2010 USD values). RESULTS: The lin-
ezolid scheme with 4-days IV (LOS4 days) and 11-days PO resulted in overall costs
per patient of 2,540 USD, while branded and generic vancomycin exhibited 3466
USD and 3663 USD, respectively. The incremental cost of vancomycin-treated pa-
tients was driven by hospital daily charges, responsible for over 60% of the overall
vancomycin costs. One-way sensitivity analysis revealed cost-savings for linezolid
up to LOS9 days, with overall costs per patient ranging from 2540-4548 USD even
if IV therapy was maintained throughout the inpatient period (LOS15 days).
CONCLUSIONS: Linezolid exhibited a cost-saving profile over branded or generic
vancomycin for the treatment of SSTI-MRSA under the Brazilian public payer per-
spective. This economic benefit was a direct result of potential early discharge of
patients receiving PO linezolid.
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OBJECTIVES: SARPAM is a programme, designed to ensure the improvement of
access to quality essential medicines in SADC. An economic appraisal was under-
taken from a societal perspective to assess the economic feasibility of SARPAM’s
implementation. The evaluative framework considered elements linked to im-
proved access to quality medicines which included regional procurement of ARVs.
The objective was to report the positive impact of this initiative on access to health
care. METHODS: Direct health care costs were estimated as the incremental in-
vestment needed to effectively implement regional cooperation processes over a 4
year period. Direct healthcare benefits were defined as the “negative costs” incurred
due to monetary savings and rational drug use. These savings were based on the
well-established advantages of regional procurement cooperation. Indirect health
care benefits were estimated using the Human Capital Approach. RESULTS: In
total, an investment of US$14 million in SARPAM (discounted at a rate of 4.5%) over
a four-year period will result in overall benefits of between US$20 million to US$38
million. The resultant benefit-cost ratio ranges from 1.40: 1 to 2.72: 1. In terms of
HIV/AIDS in South Africa in particular, the analysis estimated a potential maximum
incremental benefit of US$147 million which could treat an additional 757,000 pa-
tients with first line treatment. These results confirm that major benefits might be
derived from the SARPAM programme, including a regional procurement cooper-
ation intervention of ARVs. CONCLUSIONS: There is compelling evidence that the
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